{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.0","upperLimit":"8.6","value":"3.0"},{"groupId":"OG001","lowerLimit":"1.0","upperLimit":"4.6","value":"2.2"},{"groupId":"OG002","lowerLimit":"1.0","upperLimit":"4.2","value":"3.3"},{"groupId":"OG003","lowerLimit":"0.9","upperLimit":"5.3","value":"1.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"19"}],"units":"Participants"}],"description":"Time from Cycle 1 Day 1 to a response of PR or better.","dispersionType":"Full Range","groups":[{"description":"Participants were administered IV melflufen at a dose of 30 mg on Day 1 of each 28-day cycle in combination with SQ bortezomib at a dose of 1.3mg/m\\^2 on Days 1, 4, 8, and 11 and dexamethasone PO at a dose of 20 mg (12 mg if the participants is ≥ 75 years of age) on Days 1, 4, 8, and 11 and 40 mg (20 mg if the participants is ≥ 75 years of age) on Day 15 and 22 of each 28-day cycle.","id":"OG000","title":"A (Melflufen+Bortezomib+Dex) 30 mg"},{"description":"Participants were administered IV melflufen at a dose of 40 mg on Day 1 of each 28-day cycle in combination with SQ bortezomib at a dose of 1.3mg/m\\^2 on Days 1, 4, 8, and 11 and dexamethasone PO at a dose of 20 mg (12 mg if the participants is ≥ 75 years of age) on Days 1, 4, 8, and 11 and 40 mg (20 mg if the participants is ≥ 75 years of age) on Day 15 and 22 of each 28-day cycle.","id":"OG001","title":"A (Melflufen+Bortezomib+Dex) 40 mg"},{"description":"Participants were administered IV melflufen at a dose of 30 mg on Day 1 of each 28-day cycle in combination with IV daratumumab at a dose of 16 mg/kg weekly for 8 doses, every other week for 8 doses and then once every 4 weeks. Participants were also administered dexamethasone orally (PO) at a dose of 40 mg weekly (20 mg weekly if the participants is ≥ 75 years of age).","id":"OG002","title":"B (Melflufen+Daratumumab+Dex) 30 mg"},{"description":"Participants were administered IV melflufen at a dose of 40 mg on Day 1 of each 28-day cycle in combination with IV daratumumab at a dose of 16 mg/kg weekly for 8 doses, every other week for 8 doses and then once every 4 weeks. Participants were also administered dexamethasone orally (PO) at a dose of 40 mg weekly (20 mg weekly if the participants is ≥ 75 years of age).","id":"OG003","title":"B (Melflufen+Daratumumab+Dex) 40 mg"}],"paramType":"MEDIAN","populationDescription":"Only participants included in the Safety Analysis Set who achieved a response of PR or better were included in this analysis.","reportingStatus":"POSTED","timeFrame":"Until disease progression, death or initiation of subsequent therapy (a maximum of 194.3 weeks)","title":"Time to Response (TTR)","type":"SECONDARY","unitOfMeasure":"months"}